Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NSCLC × Liquid Biopsy × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 9 Breast Neoplasms 9 Carcinoma, Non-Small-Cell Lung 8 Lung Neoplasms 7 Pancreatic Neoplasms 5 Neoplastic Cells, Circulating 4 Neoplasm Metastasis 4 Biliary Tract Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 3 Recurrence 3 Prostatic Neoplasms 3 Oropharyngeal Neoplasms 3 Neoplasm, Residual 3 Disease 3 Nevi and Melanomas 2 Neuroendocrine Tumors 2 Neoplasms 2 Nasopharyngeal Carcinoma 2 Melanoma 2 Head and Neck Neoplasms 2 Cholangiocarcinoma 2 Carcinoma, Hepatocellular 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Uterine Cervical Dysplasia 1 Urinary Bladder Neoplasms 1 Thyroid Neoplasms 1 Stomach Neoplasms 1 Smoking 1 Sarcoma, Ewing 1

Interventions

osimertinib 11 Pemetrexed 11 Carboplatin 11 aflutinib 8 Gefitinib 8 Drug Therapy 8 Radiotherapy 6 anlotinib 5 Docetaxel 5 Cisplatin 5 pembrolizumab 4 icotinib 4 Vinorelbine 4 Radiosurgery 4 Paclitaxel 4 Gemcitabine 4 Erlotinib Hydrochloride 4 tislelizumab 3 apatinib 3 HM781-36B 3 toripalimab 2 spartalizumab 2 rezivertinib 2 dacomitinib 2 camrelizumab 2 Tyrosine Kinase Inhibitors 2 Thalidomide 2 Surgical Procedures, Operative 2 S 1 (combination) 2 Platinum 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02890849 2024-02-23

RadImm01

Xinqiao Hospital of Chongqing

Phase NA Completed

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡